All Manufacturers, Suppliers, Distributors and Exporters of MolPort-001-776-565 with Dossiers of Finished Dosage Form listed on PharmaCompass.com

PharmaCompass

Synopsis

Synopsis

ACTIVE PHARMA INGREDIENTS

0

CEP/COS

CEP/COS Certifications

0

JDMF

JDMFs Filed

0

EU WC

EU WC

0

VMF

NDC API

0

Listed Suppliers

Other Suppliers

API REF. PRICE (USD/KG)

$
$ 0

MARKET PLACE

0

FDF

0INTERMEDIATES

FINISHED DOSAGE FORMULATIONS

0

Australia

Australia

0

South Africa

South Africa

0 DRUGS IN DEVELOPMENT

FDF Dossiers

DRUG PRODUCT COMPOSITIONS

REF. STANDARDS OR IMPURITIES

0

EDQM

0

USP

0

JP

0

Others

PATENTS & EXCLUSIVITIES

0

US Exclusivities

0

Health Canada Patents

DIGITAL CONTENT

0

Stock Recap #PipelineProspector

0

Weekly News Recap #Phispers

GLOBAL SALES INFORMATION

US Medicaid

NA

Annual Reports

NA

458 RELATED EXCIPIENT COMPANIES

818EXCIPIENTS BY APPLICATIONS

Chemistry

Click the arrow to open the dropdown
read-moreClick the button for full data set
Also known as: Sulphur hexafluoride, 2551-62-4, Sulfur fluoride, Sonovue, Elegas, Sulfur fluoride (sf6)
Molecular Formula
F6S
Molecular Weight
146.06  g/mol
InChI Key
SFZCNBIFKDRMGX-UHFFFAOYSA-N
FDA UNII
WS7LR3I1D6

Sulfur Hexafluoride
Sulfur hexafluoride. An inert gas used mainly as a test gas in respiratory physiology. Other uses include its injection in vitreoretinal surgery to restore the vitreous chamber and as a tracer in monitoring the dispersion and deposition of air pollutants.
Sulfur hexafluoride is a Contrast Agent for Ultrasound Imaging. The mechanism of action of sulfur hexafluoride is as an Ultrasound Contrast Activity.
1 2D Structure

Sulfur Hexafluoride

2 Identification
2.1 Computed Descriptors
2.1.1 IUPAC Name
hexafluoro-6-sulfane
2.1.2 InChI
InChI=1S/F6S/c1-7(2,3,4,5)6
2.1.3 InChI Key
SFZCNBIFKDRMGX-UHFFFAOYSA-N
2.1.4 Canonical SMILES
FS(F)(F)(F)(F)F
2.2 Other Identifiers
2.2.1 UNII
WS7LR3I1D6
2.3 Synonyms
2.3.1 MeSH Synonyms

1. Hexafluoride, Sulfur

2.3.2 Depositor-Supplied Synonyms

1. Sulphur Hexafluoride

2. 2551-62-4

3. Sulfur Fluoride

4. Sonovue

5. Elegas

6. Sulfur Fluoride (sf6)

7. Lumason

8. Sulfur(vi) Fluoride

9. Hexafluorure De Soufre

10. Hexafluoridosulfur

11. Sulfur Hexafluoride [usan]

12. Sulfur Fluoride (sf6), (oc-6-11)-

13. Sulfur(6+) Fluoride

14. Ws7lr3i1d6

15. Chebi:30496

16. Bri

17. Hexafluorosulfur

18. Sulfur Hexafluoride (usan)

19. Esaflon

20. Elagas

21. Sf6

22. Hsdb 825

23. Hexafluorure De Soufre [french]

24. Einecs 219-854-2

25. Sulfur Hexafluoride Lipid Microsphere

26. Un1080

27. Unii-ws7lr3i1d6

28. Sf6 Microbubbles

29. Sulfur Fluoride, (oc-6-11)-

30. Lumason (tn)

31. Sonovue (tn)

32. Hexafluoro-l6-sulfane

33. Hexafluoro-lambda6-sulfane

34. Ec 219-854-2

35. R 7146

36. Hexafluoro-$l^{6}-sulfane

37. Chembl1796998

38. Dtxsid8029656

39. Sulfur Hexafluoride [mi]

40. [sf6]

41. Sulfur Hexafluoride [hsdb]

42. Sulfur Hexafluoride, >=99.75%

43. Amy37163

44. Hexakis(fluoranyl)-$l^{6}-sulfane

45. Sulfur Hexafluoride [mart.]

46. Mfcd00011447

47. Sulfur Hexafluoride [who-dd]

48. Zinc245224194

49. Db11104

50. Oc-6-11

51. Sulphur Hexafluoride [ema Epar]

52. Un 1080

53. Sonovue (for The Microbubble Formulation)

54. Stabilized Sulfur Hexafluoride Microbubbles

55. Sulfur Hexafluoride, Phospholipid Microspheres

56. D05962

57. A817889

58. Q279055

59. Sulfur Hexafluoride [un1080] [nonflammable Gas]

60. Sulfur Hexafluoride Lipid-type A Microspheres [orange Book]

2.4 Create Date
2004-09-16
3 Chemical and Physical Properties
Molecular Weight 146.06 g/mol
Molecular Formula F6S
XLogP34.2
Hydrogen Bond Donor Count0
Hydrogen Bond Acceptor Count6
Rotatable Bond Count0
Exact Mass145.96249015 g/mol
Monoisotopic Mass145.96249015 g/mol
Topological Polar Surface Area1 Ų
Heavy Atom Count7
Formal Charge0
Complexity62.7
Isotope Atom Count0
Defined Atom Stereocenter Count0
Undefined Atom Stereocenter Count0
Defined Bond Stereocenter Count0
Undefined Bond Stereocenter Count0
Covalently Bonded Unit Count1
4 Drug and Medication Information
4.1 Drug Information
1 of 2  
Drug NameLumason
Active IngredientSulfur hexafluoride lipid-type a microspheres
Dosage FormFor suspension
RouteIntravenous
Strength60.7mg/25mg
Market StatusPrescription
CompanyBracco

2 of 2  
Drug NameLumason
Active IngredientSulfur hexafluoride lipid-type a microspheres
Dosage FormFor suspension
RouteIntravenous
Strength60.7mg/25mg
Market StatusPrescription
CompanyBracco

4.2 Therapeutic Uses

Lumason is indicated for use in patients with suboptimal echocardiograms to opacify the left ventricular chamber and to improve the delineation of the left ventricular endocardial border.

NIH; DailyMed. Current Medication Information for LUMASON- sulfur hexafluoride (Revised: October 2014). Available from, as of August 2, 2015: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=7c679424-c3f7-ed02-892f-20ca0d775089


An inert gas used mainly as a test gas in respiratory physiology. Other uses include its injection in vitreoretinal surgery to restore the vitreous chamber ...

National Library of Medicine - Medical Subject Headings (2007)


The intraocular injection of sulfur hexafluoride appears to be useful contribution to the surgical treatment of superior bullous hemi-retinal detachment, allowing effective and durable internal tamponade, while avoiding prolonged bedrest.

J Fr Ophtalmol 6 (11): 889-93 (1983)


In this randomized clinical trial, 18 patients received treatment with silicone oil and 16 patients received SF6. The primary outcome was defined as successful anatomic attachment of the retina. Secondary outcomes included the time to retinal detachment, visual acuity, anatomic macular attachment, and any complications of surgery. RESULTS: The odds of successful reattachment with silicone oil were 50% greater than they were with SF6, but this difference was not statistically significant. There were no differences between the two groups in any of the secondary outcomes. ... This study did not have enough statistical power to detect a small but clinically important difference between the two treatment groups ...

PMID:9387180 Hammer M et al; Ophthalmic Surg Lasers 28 (11): 926-31 (1997)


For more Therapeutic Uses (Complete) data for SULFUR HEXAFLUORIDE (11 total), please visit the HSDB record page.


4.3 Drug Warning

/BOXED WARNING/ WARNING: SERIOUS CARDIOPULMONARY REACTIONS Serious cardiopulmonary reactions, including fatalities, have occurred uncommonly during or following the injection of ultrasound contrast agents, including sulfur hexafluoride lipid microspheres. Most serious reactions occur within 30 minutes of administration. Assess all patients for the presence of any condition that precludes administration. Always have resuscitation equipment and trained personnel readily available.

NIH; DailyMed. Current Medication Information for LUMASON- sulfur hexafluoride (Revised: October 2014). Available from, as of August 2, 2015: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=7c679424-c3f7-ed02-892f-20ca0d775089


Serious cardiopulmonary reactions, including fatalities have occurred uncommonly during or shortly following administration of ultrasound contrast agents, including Lumason. These reactions typically occurred within 30 minutes of administration. The risk for these reactions may be increased among patients with unstable cardiopulmonary conditions (acute myocardial infarction, acute coronary artery syndromes, worsening or unstable congestive heart failure, or serious ventricular arrhythmias). Always have cardiopulmonary resuscitation personnel and equipment readily available prior to Lumason administration and monitor all patients for acute reactions. The reported reactions that may follow the administration of ultrasound contrast agents include: fatal cardiac or respiratory arrest, shock, syncope, symptomatic arrhythmias (atrial fibrillation, tachycardia, bradycardia, supraventricular tachycardia, ventricular fibrillation, and ventricular tachycardia), hypertension, hypotension, dyspnea, hypoxia, chest pain, respiratory distress, stridor, wheezing, loss of consciousness, and convulsions.

NIH; DailyMed. Current Medication Information for LUMASON- sulfur hexafluoride (Revised: October 2014). Available from, as of August 2, 2015: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=7c679424-c3f7-ed02-892f-20ca0d775089


Lumason is contraindicated in patients with: known or suspected right-to-left, bi-directional, or transient right-to-left cardiac shunts history of hypersensitivity reactions to sulfur hexafluoride lipid microsphere components or to any of the inactive ingredients in Lumason Do not administer by intra-arterial injection.

NIH; DailyMed. Current Medication Information for LUMASON- sulfur hexafluoride (Revised: October 2014). Available from, as of August 2, 2015: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=7c679424-c3f7-ed02-892f-20ca0d775089


In patients with right-to-left, bi-directional, or transient right-to-left cardiac shunts, some intravenously injected sulfur hexafluoride lipid containing microspheres may bypass filtering by the lung and directly enter the arterial circulation. Occlusion of the microcirculation by these microspheres may result in tissue ischemia. Lumason is only for intravenous administration; do not administer Lumason by intra-arterial injection.

NIH; DailyMed. Current Medication Information for LUMASON- sulfur hexafluoride (Revised: October 2014). Available from, as of August 2, 2015: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=7c679424-c3f7-ed02-892f-20ca0d775089


For more Drug Warnings (Complete) data for SULFUR HEXAFLUORIDE (19 total), please visit the HSDB record page.


4.4 Drug Indication

Echocardiography: Sulfur hexafluoride is indicated for use in adult patients with suboptimal echocardiograms to opacify the left ventricular chamber and to improve the delineation of the left ventricularendocardial border. Ultrasonography of the Liver: Sulfur hexafluoride is indicated for use with ultrasound of the liver in adult and pediatric patients to characterize focal liver lesions.


This medicinal product is for diagnostic use only.

SonoVue is for use with ultrasound imaging to enhance the echogenicity of the blood, or of fluids in the urinary tract which results in an improved signal to noise ratio.

SonoVue should only be used in patients where study without contrast enhancement is inconclusive.

Echocardiography

SonoVue is a transpulmonary echocardiographic contrast agent for use in adult patients with suspected or established cardiovascular disease to provide opacification of cardiac chambers and enhance left ventricular endocardial border delineation.

Doppler of macrovasculature

SonoVue increases the accuracy in detection or exclusion of abnormalities in cerebral arteries and extracranial carotid or peripheral arteries in adult patients by improving the Doppler signal to noise ratio.

SonoVue increases the quality of the Doppler flow image and the duration of clinically useful signal enhancement in portal vein assessment in adult patients.

Doppler of microvasculature

SonoVue improves display of the vascularity of liver and breast lesions during Doppler sonography in adult patients leading to more specific lesion characterisation.

Ultrasonography of excretory urinary tract

SonoVue is indicated for use in ultrasonography of the excretory tract in paediatric patients from newborn to 18 years to detect vesicoureteral reflux. For the limitation in the interpretation of a negative urosonography.


5 Pharmacology and Biochemistry
5.1 Pharmacology

Sulfur hexafluoride provides useful echocardiographic signal intensity for two minutes after the injection. Sulfur hexafluoride microspheres are destroyed and contrast enhancement decreases as the mechanical index increases (values of 0.8 or less are recommended). For ultrasonography of the liver, Sulfur hexafluoride provides dynamic patterns of differential signal intensity enhancement between focal liver lesions and liver parenchyma during the arterial, portal venous, and late phase of signal intensity enhancement of the microvasculature.


5.2 FDA Pharmacological Classification
5.2.1 Active Moiety
SULFUR HEXAFLUORIDE
5.2.2 FDA UNII
WS7LR3I1D6
5.2.3 Pharmacological Classes
Ultrasound Contrast Activity [MoA]; Contrast Agent for Ultrasound Imaging [EPC]
5.3 ATC Code

V08DA04


V08DA05

S76 | LUXPHARMA | Pharmaceuticals Marketed in Luxembourg | Pharmaceuticals marketed in Luxembourg, as published by d'Gesondheetskeess (CNS, la caisse nationale de sante, www.cns.lu), mapped by name to structures using CompTox by R. Singh et al. (in prep.). List downloaded from https://cns.public.lu/en/legislations/textes-coordonnes/liste-med-comm.html. Dataset DOI:10.5281/zenodo.4587355


V - Various

V08 - Contrast media

V08D - Ultrasound contrast media

V08DA - Ultrasound contrast media

V08DA05 - Sulfur hexafluoride, phospholipid microspheres


5.4 Absorption, Distribution and Excretion

Absorption

The pharmacokinetic of the SF6 gas component of Lumason was evaluated in 12 healthy adult subjects (7 men and 5 women). After intravenous bolus injections of 0.03 mL/kg and 0.3 mL/kg of Lumason, corresponding to approximately 1 and 10 times the recommended doses, concentrations of SF6 in blood peaked within 1 to 2 minutes for both doses.


Route of Elimination

The SF6 component of Lumason is eliminated via the lungs.


Volume of Distribution

In a study of healthy subjects, the mean values for the apparent steady-state volume of distribution of SF6 were 341 L and 710 L for Lumason doses of 0.03 mL/kg and 0.3 mL/kg, respectively. Preferential distribution to the lung is likely responsible for these values.


SonoVue, is a new echo contrast agent based on stabilized sulfur hexafluoride (SF6) microbubbles ... The blood kinetics and pulmonary elimination of SF6 after intravenous bolus injection of two dosage levels (0.03 and 0.3 mL/kg) of SonoVue were evaluated in 12 healthy subjects (7 men, 5 women). In addition, safety and tolerability were evaluated by monitoring vital signs, adverse effects, discomfort, and physical examination and laboratory parameters associated with the SonoVue injection. The blood kinetics of SF6 was not dose dependent. SF6 was rapidly removed from the blood by the pulmonary route, with 40% to 50% of the injected dose eliminated within the first minute after administration and 80% to 90% eliminated by 11 minutes after administration; the elimination was similar in men and women and independent of dose. Both dosages were well tolerated. No adverse effects were observed immediately or during the 24-hour follow-up period. ... The route of SF6 elimination was by means of the lungs in the expired air. ...

PMID:10639039 Morel DR et al; Invest Radiol 35 (1): 80-5 (2000)


Sonovue (trade mark) is a new echo contrast agent made of microbubbles stabilized by phospholipids and containing sulphur hexafluoride (SF6), an innocuous gas. ... With regard to the gas contained in the bubbles, its pharmacokinetics have been assessed during a study in human volunteers. Following intravenous administration of 0.3 mL/kg of SonoVue (trade mark) (i.e., approximately ten times the imaging dose), the blood level curve showed a distribution half-life of about 1 minute and an elimination half-life of about 6 minutes. More than 80% of the administered gas is exhaled via the lungs after 11 minutes. ...

PMID:10639039 Schneider M; Echocardiography 16 (7, Pt 2): 743-746 (1999 Oct)


The pharmacokinetic of the SF6 gas component of Lumason was evaluated in 12 healthy adult subjects (7 men and 5 women). After intravenous bolus injections of 0.03 mL/kg and 0.3 mL/kg of Lumason, corresponding to approximately 1 and 10 times the recommended doses, concentrations of SF6 in blood peaked within 1 to 2 minutes for both doses. The terminal half-life of SF6 in blood was approximately 10 minutes for the 0.3 mL/kg dose. (At the 0.03 mL/kg dose, terminal half-life could not be estimated.) The area-under-the-curve of SF6 was dose-proportional over the dose range studied.

NIH; DailyMed. Current Medication Information for LUMASON- sulfur hexafluoride (Revised: October 2014). Available from, as of August 2, 2015: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=7c679424-c3f7-ed02-892f-20ca0d775089


In a study of healthy subjects, the mean values for the apparent steady-state volume of distribution of SF6 were 341 L and 710 L for Lumason doses of 0.03 mL/kg and 0.3 mL/kg, respectively. Preferential distribution to the lung is likely responsible for these values.

NIH; DailyMed. Current Medication Information for LUMASON- sulfur hexafluoride (Revised: October 2014). Available from, as of August 2, 2015: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=7c679424-c3f7-ed02-892f-20ca0d775089


For more Absorption, Distribution and Excretion (Complete) data for SULFUR HEXAFLUORIDE (6 total), please visit the HSDB record page.


5.5 Metabolism/Metabolites

SF6 undergoes little or no biotransformation; 88% of an administered dose is recovered unchanged in expired air.


SF6 undergoes little or no biotransformation; 88% of an administered dose is recovered unchanged in expired air.

NIH; DailyMed. Current Medication Information for LUMASON- sulfur hexafluoride (Revised: October 2014). Available from, as of August 2, 2015: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=7c679424-c3f7-ed02-892f-20ca0d775089


Under brief and prolonged exposures, sulfur hexafluoride was biologically inert and did not metabolize.

PMID:7250729 Mel'nikova LV, Rozova TA; Gig Tr Prof Zabol 6: 48-9 (1981)


5.6 Biological Half-Life

The terminal half-life of SF6 in blood was approximately 10 minutes for the 0.3 mL/kg dose. (At the 0.03 mL/kg dose, terminal half-life could not be estimated.)


The pharmacokinetic of the SF6 gas component of Lumason was evaluated in 12 healthy adult subjects (7 men and 5 women). After intravenous bolus injections of 0.03 mL/kg and 0.3 mL/kg of Lumason... The terminal half-life of SF6 in blood was approximately 10 minutes for the 0.3 mL/kg dose. (At the 0.03 mL/kg dose, terminal half-life could not be estimated.) The area-under-the-curve of SF6 was dose-proportional over the dose range studied.

NIH; DailyMed. Current Medication Information for LUMASON- sulfur hexafluoride (Revised: October 2014). Available from, as of August 2, 2015: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=7c679424-c3f7-ed02-892f-20ca0d775089


... Following intravenous administration of 0.3 mL/kg of SonoVue (trade mark) (i.e., approximately ten times the imaging dose), the blood level curve showed a distribution half-life of about 1 minute and an elimination half-life of about 6 minutes. ...

PMID:10639039 Schneider M; Echocardiography 16 (7, Pt 2): 743-746 (1999 Oct)


In a study of patients with pulmonary impairment, blood concentrations of SF6 peaked at 1 to 4 minutes following Lumason administration. The cumulative recovery of SF6 in expired air was 102 +/- 18% (mean +/- standard deviation), and the terminal half-life of SF6 in blood was similar to that measured in healthy subjects.

NIH; DailyMed. Current Medication Information for LUMASON- sulfur hexafluoride (Revised: October 2014). Available from, as of August 2, 2015: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=7c679424-c3f7-ed02-892f-20ca0d775089


5.7 Mechanism of Action

Within the blood, the acoustic impedance of Lumason microspheres is lower than that of the surrounding non-aqueous tissue. Therefore, an ultrasound beam is reflected from the interface between the microspheres and the surrounding tissue. The reflected ultrasound signal provides a visual image that shows a contrast between the blood and the surrounding tissues.


USDMF

read-more
read-more

01

BioProcess International
Not Confirmed

01

BioProcess International
Not Confirmed

GDUFA

DMF Review : N/A

Rev. Date :

Pay. Date :

DMF Number : 15094

Submission : 2000-10-13

Status : Active

Type : II

blank

02

Fluoromed Lp

U.S.A

USDMF

arrow
BioProcess International
Not Confirmed

02

Fluoromed Lp

U.S.A
arrow
BioProcess International
Not Confirmed

GDUFA

DMF Review : N/A

Rev. Date :

Pay. Date :

DMF Number : 37317

Submission : 2023-03-24

Status : Active

Type : II

blank

03

Medi Physics Inc

United Kingdom

USDMF

arrow
BioProcess International
Not Confirmed

03

Medi Physics Inc

United Kingdom
arrow
BioProcess International
Not Confirmed

GDUFA

DMF Review : N/A

Rev. Date :

Pay. Date :

DMF Number : 1888

Submission : 1972-03-08

Status : Inactive

Type : II

blank
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

KDMF

read-more
read-more

01

BioProcess International
Not Confirmed
arrow
arrow
BioProcess International
Not Confirmed

Sulfahexafluoride

Registrant Name : Braco Imaging Korea Co., Ltd.

Registration Date : 2005-06-14

Registration Number : Number 267-1-ND

Manufacturer Name : Airgas Therapeutics, LLC

Manufacturer Address : 6141 Easton Road-Building 3, Plumsteadville, PA 18949-0310

blank
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

FDA Orange Book

read-more
read-more

01

BRACCO

Italy
BioProcess International
Not Confirmed
arrow

BRACCO

Italy
arrow
BioProcess International
Not Confirmed

SULFUR HEXAFLUORIDE LIPID-TYPE A MICROSPHERES

Brand Name : LUMASON

Dosage Form : FOR SUSPENSION;INTRAVENOUS

Dosage Strength : 60.7MG/25MG

Approval Date : 2014-10-15

Application Number : 203684

RX/OTC/DISCN : RX

RLD : Yes

TE Code :

blank

02

POYTHRESS

United Kingdom
BioProcess International
Not Confirmed
arrow

POYTHRESS

United Kingdom
arrow
BioProcess International
Not Confirmed

SULFUR

Brand Name : BENSULFOID

Dosage Form : POWDER;TOPICAL

Dosage Strength : 33.32%

Approval Date : 1982-01-01

Application Number : 2918

RX/OTC/DISCN : DISCN

RLD : No

TE Code :

blank
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Europe

read-more
read-more

01

BioProcess International
Not Confirmed
arrow
arrow
BioProcess International
Not Confirmed

sulfur hexafluoride

Brand Name : SonoVue

Dosage Form : POWDER AND SOLVENT FOR SOLUTION FOR INJECTION

Dosage Strength : 8 MICROL / ML

Packaging :

Approval Date :

Application Number :

Regulatory Info :

Registration Country : Sweden

blank

02

BioProcess International
Not Confirmed
arrow
arrow
BioProcess International
Not Confirmed

Sulfur Hexafluoride

Brand Name : Sonovue

Dosage Form : Sulfur Hexafluoride, 8Mcl/Ml 5Ml 1 Units Parenteral Use

Dosage Strength : 8 mcl/ml 1 vial + 1 syringe 5 ml + Adapter

Packaging :

Approval Date :

Application Number :

Regulatory Info :

Registration Country : Italy

blank

03

BioProcess International
Not Confirmed
arrow
arrow
BioProcess International
Not Confirmed

Sulfur Hexafluoride

Brand Name : SonoVue

Dosage Form : Powder and liquid to the injection fluid, Dispersion

Dosage Strength : 8 micro liters/ml

Packaging : Set

Approval Date :

Application Number :

Regulatory Info :

Registration Country : Norway

blank

04

BioProcess International
Not Confirmed
arrow
arrow
BioProcess International
Not Confirmed

Sulfur hexafluoride

Brand Name : Sonovue

Dosage Form : Dry Sub C Solv

Dosage Strength :

Packaging :

Approval Date :

Application Number :

Regulatory Info :

Registration Country : Switzerland

blank

05

BioProcess International
Not Confirmed
arrow
arrow
BioProcess International
Not Confirmed

Selenium disulfide; Sulfur

Brand Name : Ektoselen medicinal shampoo

Dosage Form : Solution

Dosage Strength :

Packaging :

Approval Date :

Application Number :

Regulatory Info :

Registration Country : Switzerland

blank

06

BioProcess International
Not Confirmed
arrow
arrow
BioProcess International
Not Confirmed

Selenium disulfide; Sulfur

Brand Name : Ektoselen medicinal shampoo

Dosage Form : Solution

Dosage Strength :

Packaging :

Approval Date :

Application Number :

Regulatory Info :

Registration Country : Switzerland

blank
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Canada

read-more
read-more

01

BioProcess International
Not Confirmed
arrow
arrow
BioProcess International
Not Confirmed

SULFUR HEXAFLUORIDE

Brand Name : SONOVUE

Dosage Form : POWDER FOR SUSPENSION

Dosage Strength : 8MCL/ML

Packaging :

Approval Date :

Application Number : 2287684

Regulatory Info : Ethical

Registration Country : Canada

blank
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Listed Dossiers

read-more
read-more

01

Teknomek

Turkey
BioProcess International
Not Confirmed
arrow

Teknomek

Turkey
arrow
BioProcess International
Not Confirmed

Sulfur Hexafluoride

Brand Name :

Dosage Form : Ophthalmic Gas

Dosage Strength : 10ML

Packaging :

Approval Date :

Application Number :

Regulatory Info :

Registration Country : Turkey

blank

01

Teknomek

Turkey
BioProcess International
Not Confirmed
arrow

Teknomek

Turkey
arrow
BioProcess International
Not Confirmed

Sulfur Hexafluoride

Dosage : Ophthalmic Gas

Dosage Strength : 10ML

Brand Name :

Approval Date :

Application Number :

Registration Country : Turkey

blank
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Related Excipient Companies

Upload your portfolio for free, ask us

Excipients by Applications

Click here to find the perfect excipient manufacturers by their capabilities

Fillers, Diluents & Binders

read-more
read-more

01

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothRochem, your partner in developing, sourcing, and supplying pharmaceutical & animal health ingredients of Chinese origin.

Grade : Oral

Category : Fillers, Diluents & Binders, Taste Masking

click full view

Topical

read-more
read-more

01

Evonik

Germany
  • fda
  • EDQM
  • WHO-GMP

Virtual BoothEvonik's CDMO solutions for APIs and HPAPIs: It specializes where the client needs it most!

Grade : Oral, Topical

Category : Lubricants & Glidants, Taste Masking, Topical

03

DKSH

Switzerland
  • fda
  • EDQM
  • WHO-GMP

Virtual BoothDKSH is your trusted partner for companies looking to grow their business in Asia & beyond.

Grade : Topical, Parenteral

Category : Solubilizers, Topical

08

DKSH

Switzerland
  • fda
  • EDQM
  • WHO-GMP

Virtual BoothDKSH is your trusted partner for companies looking to grow their business in Asia & beyond.

Grade : Topical

Category : Topical

Brand Name : BORIC ACID

Excipient Details : Boric acid is used as an antimicrobial preservative in topical formulations such as creams and ointments.

Pharmacopoeia Ref : EP

Technical Specs : 99.9 % Boric Acid (H3BO3)

arrow

09

DKSH

Switzerland
  • fda
  • EDQM
  • WHO-GMP

Virtual BoothDKSH is your trusted partner for companies looking to grow their business in Asia & beyond.

Grade : Topical

Category : Topical

10

click full view

Solubilizers

read-more
read-more

Thickeners and Stabilizers

read-more
read-more

Coating Systems & Additives

read-more
read-more

Direct Compression

read-more
read-more

Parenteral

read-more
read-more

Controlled & Modified Release

read-more
read-more

Emulsifying Agents

read-more
read-more

Granulation

read-more
read-more

Taste Masking

read-more
read-more

Film Formers & Plasticizers

read-more
read-more

Surfactant & Foaming Agents

read-more
read-more

Lubricants & Glidants

read-more
read-more

Chewable & Orodispersible Aids

read-more
read-more

Co-Processed Excipients

read-more
read-more

Disintegrants & Superdisintegrants

read-more
read-more

Rheology Modifiers

read-more
read-more

API Stability Enhancers

read-more
read-more
click full view

Empty Capsules

read-more
read-more

Coloring Agents

read-more
read-more

Vegetarian Capsules

read-more
read-more

Soft Gelatin

read-more
read-more

Digital Content read-more

Create Content with PharmaCompass, ask us

DATA COMPILATION #PharmaFlow

read-more
read-more

NEWS #PharmaBuzz

read-more
read-more

Global Sales Information

Do you need Business Intel? Ask us

Finished Drug Prices

read-more
read-more

01

Brand Name : Sonovue

Italy
arrow
BioProcess International
Not Confirmed

Brand Name : Sonovue

Italy
arrow
BioProcess International
Not Confirmed

Sulfur Hexafluoride

Dosage Form : Dry Sub C Solv

Dosage Strength :

Price Per Pack (Euro) : 80.9

Published in :

Country : Switzerland

RX/OTC/DISCN : Class B

blank

02

Brand Name : SonoVue

Italy
arrow
BioProcess International
Not Confirmed

Brand Name : SonoVue

Italy
arrow
BioProcess International
Not Confirmed

Sulfur Hexafluoride

Dosage Form : Powder and liquid to the injecti...

Dosage Strength : 8 micro liters/ml

Price Per Pack (Euro) : 77.275

Published in :

Country : Norway

RX/OTC/DISCN :

blank

03

Brand Name : Ektoselen medicinal shampoo

France
arrow
BioProcess International
Not Confirmed

Brand Name : Ektoselen medicinal shampoo

France
arrow
BioProcess International
Not Confirmed

Selenium Sulfide; Sulfur Hexafluoride

Dosage Form : Solution

Dosage Strength :

Price Per Pack (Euro) : 5

Published in :

Country : Switzerland

RX/OTC/DISCN : Class D

blank

04

Brand Name : Ektoselen medicinal shampoo

France
arrow
BioProcess International
Not Confirmed

Brand Name : Ektoselen medicinal shampoo

France
arrow
BioProcess International
Not Confirmed

Selenium Sulfide; Sulfur Hexafluoride

Dosage Form : Solution

Dosage Strength :

Price Per Pack (Euro) : 9.51

Published in :

Country : Switzerland

RX/OTC/DISCN : Class D

blank

05

Brand Name : Sonovue

Italy
arrow
BioProcess International
Not Confirmed

Brand Name : Sonovue

Italy
arrow
BioProcess International
Not Confirmed

Sulfur Hexafluoride

Dosage Form : Sulfur Hexafluoride, 8Mcl/Ml 5Ml...

Dosage Strength : 8 mcl/ml 1 vial + 1 syringe 5 ml + Adapter

Price Per Pack (Euro) : 101.27

Published in :

Country : Italy

RX/OTC/DISCN : Class H

blank
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Market Place

Do you need sourcing support? Ask us

Patents & EXCLUSIVITIES

Check the patents & exclusivity for this product

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty